Recent evidence suggests that the cancer cells in the primary tumor can precondition distant sites to be maximally receptive for metastasis. However, the mechanisms through which primary tumor cancer cells educate the distant site are not well defined. Exosomes are small microvesicles that are shed from many cells, including cancer cells. We have preliminarily identified that primary tumor PCa cells produce exosomes that can target bone marrow stromal cells (BMSC) and increase expression of pyruvate kinase isoenzyme M2 (PKM2) in the BMSC. PKM2 induces a positive energy balance in cells and promotes production of potential sources of energy that can enrich the local environment. Furthermore, we have found that exosome PKM2 content increases with tumor stage. Accordingly, we hypothesize that primary tumor-derived exosomes alter the metabolic status of the distant bone microenvironment to create a favorable pre-metastatic niche through increasing PKM2 expression in BMSC. To test this hypothesis we will perform the following Aims.
Aim 1 : Determine changes in exosomes as primary PCa progresses that enable them to create a pre- metastatic niche in bone.
Aim 2 : Determine the mechanisms through which the exosome-mediated increase of PKM2 in BMSCs create a pre-metastatic niche that promotes metastatic progression. In particular, metabolic changes in the bone microenvironment will be explored Aim 3: Determine prognostic value of PKM2 expression in serum-derived exosomes of PCa patients. When completed, this research will provide both translational and mechanistic insight into how the primary tumor creates a pre-metastatic niche and established the concept that primary tumor-derived exosomes alter the metabolic state of the distant site to favor metastatic growth. Additionally, we will have determined if exosome PKM2 level provides prognostic significance in PCa patients.

Public Health Relevance

Prostate cancer (PCa) is the most common cancer of American men and the second leading cause of cancer- related death most often due to bone metastasis. This project will explore how the cancer changes the bone environment so that it becomes conducive to bone metastasis. This will help identify targets to prevent or treat bone metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA093900-13
Application #
9312752
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
2004-06-05
Project End
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
13
Fiscal Year
2017
Total Cost
$241,798
Indirect Cost
$52,911
Name
University of Michigan Ann Arbor
Department
Type
Domestic Higher Education
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Hill, Elliott E; Kim, Jin Koo; Jung, Younghun et al. (2018) Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J Cell Biochem 119:8074-8083
Axelrod, Haley D; Valkenburg, Kenneth C; Amend, Sarah R et al. (2018) AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Mol Cancer Res :
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266
Wu, Amy; Liao, David; Kirilin, Vlamimir et al. (2018) Cancer dormancy and criticality from a game theory perspective. Cancer Converg 2:1
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Lee, Eunsohl; Wang, Jingcheng; Jung, Younghun et al. (2018) Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer. J Cell Biochem 119:3697-3705
van der Toom, Emma E; Axelrod, Haley D; de la Rosette, Jean J et al. (2018) Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nat Rev Urol :
Roca, Hernan; McCauley, Laurie K (2018) Efferocytosis and prostate cancer skeletal metastasis: implications for intervention. Oncoscience 5:174-176

Showing the most recent 10 out of 228 publications